Navigation Links
Zix Corporation and Humana Renew and Expand Exclusive Agreement
Date:9/2/2009

DALLAS, Sept. 2 /PRNewswire-FirstCall/ -- Zix Corporation (ZixCorp(R)), (Nasdaq: ZIXI), the leader in email encryption services, today announced that Humana renewed its contract with ZixCorp. This latest agreement is a two-year extension of Humana's original agreement which has now spanned seven successful years. This latest contract also expands the number of ZixCorp licenses bringing the total to 36,000.

Humana is a Fortune 100 corporation with more than 28,000 associates serving the health benefits needs of 10.4 million members. A corporation of this size and sophistication demands reliability and scalability from its vendors. ZixCorp was founded on a model that envisioned massive scale delivered via a professionally certified data center. ZixCorp has attained the highest level of certification through its SysTrust(TM) accreditation. This vision, coupled with proven execution, has allowed ZixCorp to continue its successful role as Humana's exclusive email encryption service.

Humana utilizes ZixCorp email encryption services across the entire spectrum of their business communications. ZixCorp delivers HIPAA-compliant email encryption services for internal Humana communication as well as seamless external communication with members and business partners. As a ZixCorp customer, Humana users benefit from access to ZixDirectory, the largest email encryption directory in the world. ZixDirectory enables the entire Humana community to send and receive secure email through a SaaS architecture that delivers seamless key management "in the cloud."

"ZixCorp's email encryption services continue to be the first choice in the healthcare community because of our relentless focus on quality and reliability," said Rick Spurr, Chief Executive Officer for ZixCorp.

About Zix Corporation

Zix Corporation (ZixCorp(R)) is the leading provider of hosted email encryption and payor sponsored e-prescribing services. ZixCorp's email encryption services provide an easy and cost-effective way to ensure customer privacy and regulatory compliance for corporate email. ZixCorp offers the simplicity of Software as a Service with the convenience of customizable encryption policies. ZixCorp operates the largest email encryption directory in the world enabling seamless and secure communication among communities of interest. ZixCorp's directory connects over 17 million members and includes over 20 state banking regulators, over 1000 financial institutions, over 1000 hospitals and over 30 Blue Cross Blue Shield organizations. ZixCorp's PocketScript(R) e-prescribing service reduces costs and improves patient care by automating the prescription process between payers, doctors, and pharmacies. For more information, visit www.zixcorp.com.


'/>"/>
SOURCE Zix Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Brooke Franchise Corporation Announces Selected July Results
3. MedThink Communications Retained by NanoBio Corporation
4. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
5. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
6. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
7. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
8. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
9. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
10. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
11. AGA Medical Corporation Receives Approval for the AMPLATZER Muscular Ventricular Septal Defect Occluder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: